Attenuated Actinobacillus pleuropneumoniae as a bacterial vector for expression of Mycoplasma hyopneumoniae P36 gene

Journal of Gene Medicine

Volumn 13, Issue 4, 2011, Pages 221-229

  Zou, Hao Yong ^a   Liu, Xin Jun ^a   Ma, Feng Ying ^a   Chen, Pin ^a   Zhou, Rui ^a   He, Qi Gai ^a  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

Actinobacillus pleuropneumoniae; Attenuate; Bacterial vector; Mycoplasma hyopneumoniae; Vaccine

Indexed keywords

ANTIBODY; BACTERIAL VACCINE; BACTERIAL VECTOR; CELL ANTIGEN; DODECYL SULFATE SODIUM; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; LIVE VACCINE; UREASE;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM MUTANT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IN VITRO STUDY; MOUSE; MYCOPLASMA HYOPNEUMONIAE; MYCOPLASMAL PNEUMONIA OF SWINE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PORCINE PLEUROPNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STRUCTURAL GENE; WESTERN BLOTTING; WHOLE CELL;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMALS; BLOTTING, WESTERN; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; L-LACTATE DEHYDROGENASE; MICE; MYCOPLASMA HYOPNEUMONIAE; PNEUMONIA OF SWINE, MYCOPLASMAL; SWINE; UREASE; VACCINES, ATTENUATED; VIRULENCE;

ACTINOBACILLUS PLEUROPNEUMONIAE; BACTERIA (MICROORGANISMS); MYCOPLASMA HYOPNEUMONIAE; SUIDAE; SUS;

EID: 79955131254     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1556     Document Type: Article

References (41)

1. Ross RF. mycoplasma diseases. In Diseases of Swine, Straw BE, D'Allaire S, Mengeling WL, Taylor DJ (eds). Iowa State University Press: Ames, IA, 1999; 495-501.
2. Taylor DJ. Actinobacillus pleuropneumoniae. In Diseases of Swine, Straw BE, D'Allaire S, Mengeling WL, Taylor DJ (eds). Iowa State University Press: Ames, IA, 1999; 343-354.
3. Kobisch M, Labbe A, Morvan P, et al. Pathologie pulmonaire du porc: unmode' le experimental associant Mycoplasma hyopneumoniae et Actinobacillus pleuropneumoniae. J. Recherche Porcine 1993; 25: 339-344.
4. Gottschalk M, Taylor T. Actinobacillus pleuropneumoniae. In Diseases of Swine (9th edn), Straw BE, Zimmerman JJ, D'Allaire S, Taylor DJ (eds). Blackwell Publishing Ltd: Oxford, 2006; 563-576.
5. Bosse JT, MacInnes JI. Genetic and biochemical analyses of Actinobacillus pleuropneumoniae urease. Infect Immun 1997; 65: 4389-4394.
6. Frey J. Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Trends Microbiol 1995; 3: 257-261.
7. Inzana TJ. Virulence properties of Actinobacillus pleuropneumoniae. Microb Pathog 1991; 11: 305-316.
8. Prideaux CT, Pierce L, Krywult J, et al. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination. Curr Microbiol 1998; 37: 324-332.
9. Ingham A, Zhang Y, Prideaux C. Attenuation of Actinobacillus pleuropneumoniae by inactivation of aroQ. Vet Microbiol 2002; 84: 263-273.
10. Xu F, Chen X, Shi A, et al. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae. Vet Microbiol 2006; 118: 230-239.
11. Bei W, He Q, Yan L, et al. Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker. FEMS Microbiol Lett 2005; 243: 21-27.
12. Bei W, He Q, Zhou R, et al. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs. Vet Microbiol 2007; 125: 120-127.
13. Tonpitak W, Baltes N, Hennig-Pauka, et al. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine. Infect Immun 2002; 70: 7120-7125.
14. Maas A, Jacobsen ID, Meens J, et al. Use of an Actinobacillus pleuropneumoniae multiple mutant as a vaccine that allows differentiation of vaccinated and infected animals. Infect Immun 2006; 74: 4124-4132.
15. Haga Y, Ogino S, Ohashi S, et al. Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia. J Vet Med Sci 1997; 59: 115-120.
16. Seah JN, Frey J, Kwang J. The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice. Infect Immun 2002; 70(11): 6464-6467.
17. Meeusen EN, Walker J, Peters A, et al. Current status of veterinary vaccines. Clin Microbiol Rev 2007; 20: 489-510.
18. Chen AY, Fry SR, Forbes-Faulkner J, et al. Evaluation of the immunogenicity of the P97R1 adhesin of Mycoplasma hyopneumoniae as a mucosal vaccine in mice. J Med Microbiol 2006; 55: 923-929.
19. Fagan PK, Djordjevic SP, Chin J, et al. Oral immunization of mice with attenuated Salmonella typhimurium aroA expressing a recombinant Mycoplasma hyopneumoniae antigen (NrdF). Infect Immun 1997; 65: 2502-2507.
20. Matic JN, Terry TD, Van Bockel D, et al. Development of non-antibiotic-resistant, chromosomally based, constitutive and inducible expression systems for aroA-attenuated Salmonella enterica Serovar Typhimurium. Infect Immun 2009; 77: 1817-1826.
21. Zhao Z, Xue Y, Wu B, et al. Subcutaneous vaccination with attenuated Salmonella enterica serovar Choleraesuis C500 expressing recombinant filamentous hemagglutinin and pertactin antigens protects mice against fatal infections with both S. enterica serovar Choleraesuis and Bordetella bronchiseptica. Infect Immun 2008; 76: 2157-2163.
22. Shimoji Y, Oishi E, Kitajima T, et al. Erysipelothrix rhusiopathiae YS-1 as a live vaccine vehicle for heterologous protein expression and intranasal immunization of pigs. Infect Immun 2002; 70: 226-232.
23. Shimoji Y, Oishi E, Muneta Y, et al. Vaccine efficacy of the attenuated Erysipelothrix rhusiopathiae YS-19 expressing a recombinant protein of Mycoplasma hyopneumoniae P97 adhesin against mycoplasmal pneumonia of swine. Vaccine 2003; 21: 532-537.
24. Ogawa Y, Oishi E, Muneta Y, et al. Oral vaccination against mycoplasmal pneumonia of swine using a live Erysipelothrix rhusiopathiae vaccine strain as a vector. Vaccine 2009; 27: 4543-4550.
25. Cruijsen T, van Leengoed LA, Ham-Hoffies M, et al. Convalescent pigs are protected completely against infection with a homologous Actinobacillus pleuropneumoniae strain but incompletely against a heterologous-serotype strain. Infect Immun 1995; 63: 2341-2343.
26. Lin L, Bei W, Sha Y, et al. Construction and immunogencity of a DeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar 1. FEMS Microbiol Lett 2007; 274: 55-62.
27. Strasser M, Frey J, Bestetti G, et al.Cloning and expression of a species-specific early immunogenic 36-kilodalton protein of Mycoplasma hyopneumoniae in Escherichia coli. Infect Immun 1991; 59: 1217-1222.
28. Yao R, He Q, Zhou R, et al. Cloning expression of Mycoplasma hyopneumoniae LDH gene and development of indirect ELISA for antibody detection. China J Vet Sci 2007; 27: 511-515.
29. Oswald W, Tonpitak W, Ohrt G, et al. A single-step transconjugation system for the introduction of unmarked deletions into Actinobacillus pleuropneumoniae serotype 7 using a sucrose sensitivity marker. FEMS Microbiol Lett 1999; 179: 153-160.
30. Dehio C, Meyer M. Maintenance of broad-host-range incompatibility group P and group Q plasmids and transposition of Tn5 in Bartonella henselae following conjugal plasmid transfer from Escherichia coli. J Bacteriol 1997; 179: 538-540.
31. Reed LJ, Muench H. A simple method of estimating 50 percentage endpoints. J Am Hygiene 1938; 27: 493-497.
32. Thacker EL. Mycoplasmal diseases. In Diseases of Swine (9th edn), Straw BE, Zimmerman JJ, D'Allaire S, Taylor DJ (eds). Blackwell Publishing Ltd: Oxford, 2006; 701-717.
33. Noyes EP, Feeney DA, Pijoan C. Comparison of the effect of pneumonia detected during lifetime with pneumonia detected at slaughter on growth in swine. J Am Vet Med Assoc 1990; 197: 1025-1029.
34. Prideaux CT, Lenghaus C, Krywult J, et al. Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon. Infect Immun 1999; 67: 1962-1966.
35. O'Dwyer CA, Reddin K, Martin D, et al. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect Immun 2004; 72: 6511-6518.
36. Litt DJ, Palmer HM, Borriello SP. Neisseria meningitidis expressing transferrin binding proteins of Actinobacillus pleuropneumoniae can utilize porcine transferrin for growth. Infect Immun 2000; 68: 550-557.
37. Yamao F, Muto A, Kawauchi Y, et al. 1985. UGA is read as tryptophan in Mycoplasma capricolum. Proc Natl Acad Sci USA 1985; 82: 2306-2309.
38. Bosse JT, MacInnes JI. Urease activity may contribute to the ability of Actinobacillus pleuropneumoniae to establish infection. Can J Vet Res 2000; 64: 145-150.
39. Baltes N, Tonpitak W, Gerlach GF, Hennig-Pauka I, Hoffmann-Moujahid A, Ganter M, Rothkotter HJ. Actinobacillus pleuropneumoniae iron transport and urease activity: effects on bacterial virulence and host immune response. Infect Immun 2001; 69: 472-478.
40. Baltes N, Hennig-Pauka I, Gerlach GF. Both transferrin binding proteins are virulence factors in Actinobacillus pleuropneumoniae serotype 7 infection. FEMS Microbiol Lett 2002; 209: 283-287.
41. Edwards RA, Keller LH, Schifferli DM. Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression. Gene 1998; 207: 149-157.